REDHILL BIOPHAR/S (RDHL) & Dicerna Pharmaceuticals (NASDAQ:DRNA) Financial Contrast

REDHILL BIOPHAR/S (NASDAQ: RDHL) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for REDHILL BIOPHAR/S and Dicerna Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
REDHILL BIOPHAR/S 1 0 5 0 2.67
Dicerna Pharmaceuticals 0 3 4 0 2.57

REDHILL BIOPHAR/S presently has a consensus price target of $22.60, indicating a potential upside of 247.69%. Dicerna Pharmaceuticals has a consensus price target of $14.80, indicating a potential upside of 1.37%. Given REDHILL BIOPHAR/S’s stronger consensus rating and higher possible upside, research analysts plainly believe REDHILL BIOPHAR/S is more favorable than Dicerna Pharmaceuticals.

Institutional and Insider Ownership

20.0% of REDHILL BIOPHAR/S shares are owned by institutional investors. Comparatively, 79.2% of Dicerna Pharmaceuticals shares are owned by institutional investors. 19.9% of Dicerna Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares REDHILL BIOPHAR/S and Dicerna Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
REDHILL BIOPHAR/S $4.01 million 34.48 -$45.54 million ($2.60) -2.50
Dicerna Pharmaceuticals $2.28 million 339.07 -$60.04 million ($3.66) -3.99

REDHILL BIOPHAR/S has higher revenue and earnings than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than REDHILL BIOPHAR/S, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

REDHILL BIOPHAR/S has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500.

Profitability

This table compares REDHILL BIOPHAR/S and Dicerna Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
REDHILL BIOPHAR/S -726.64% -114.27% -86.82%
Dicerna Pharmaceuticals -1,642.81% -97.39% -61.25%

Summary

REDHILL BIOPHAR/S beats Dicerna Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

REDHILL BIOPHAR/S Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs. Its principal clinical-stage development programs comprise TALICIA (RHB-105) for Helicobacter pylori infection; RHB-104 for Crohn's disease; RHB-204 for nontuberculous mycobacteria infections; BEKINDA (RHB-102) for acute gastroenteritis and gastritis and diarrhea-predominant irritable bowel syndrome; YELIVA (ABC294640) for cholangiocarcinoma, as well as targeting other oncology, inflammatory, and gastrointestinal indications; RHB-106, an encapsulated bowel preparation; and RHB-107 for cancer and inflammatory gastrointestinal diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; and a license agreement with City of Hope. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply